Skip to content

Establishment and maintenance of the epidemiology, pathology, clinical treatment and prognosis database (DEPARTURE DATABASE) of upper tract urothelial carcinoma in Chinese population: a bidirectional cohort study

Establishment and maintenance of the epidemiology, pathology, clinical treatment and prognosis database (DEPARTURE DATABASE) of upper tract urothelial carcinoma in Chinese population: a bidirectional cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101254
Enrollment
Unknown
Registered
2025-04-22
Start date
2021-05-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upper tract urothelial carcinoma

Interventions

Case series:N/A

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Retrospective group inclusion criteria: Patients with pathologically confirmed UTUC who had previously received treatment in the Department of Urology at Peking University First Hospital; Prospective team inclusion criteria: (1) 18<= age <=90 years old, gender is not limited; (2) Patients with hematuria, low back pain and other chief complaints, complete diagnosis and treatment routine examination such as: chest X-ray/chest CT, B ultrasound, abdominal pelvic/urinary system enhanced CT/MRU, urine cytology, cystoscopy or ureteroscopy and other auxiliary examination of preliminary diagnosis of upper urinary tract carcinoma, and confirmed by surgery or biopsy. (3) Patients voluntarily participate and sign informed consent forms. (4) Easy to understand and judge the requirements of clinical research.

Exclusion criteria

Exclusion criteria: (1) Patients refused surgery or data collection. (2) Patients with contraindications to anesthesia or surgery, such as cardiopulmonary and liver insufficiency decompensation, diseases prone to severe bleeding, and unstable glycemic control of diabetes mellitus, etc.

Design outcomes

Primary

MeasureTime frame
Overall survival;

Secondary

MeasureTime frame
Cancer specific survival;progression free survival;Recurrence-free survival;Local recurrence-free survival;bladder-recurrence free survival;metastasis-free survival;

Countries

China

Contacts

Public ContactLiqun Zhou

Peking University First Hospital

zhoulqmail@sina.com+86 83572211

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026